These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 37676002)
21. A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model. Ma J; Liu X; Zhou M; Chen P; Chen R; Wang J; Zhu H; Wu K; Ye J; Zhang Y; Yuan Q; Tang Q; Yuan L; Cheng T; Guan Y; Xia N J Virol; 2023 Feb; 97(2):e0168422. PubMed ID: 36651747 [TBL] [Abstract][Full Text] [Related]
22. The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5. Shuai H; Chan JF; Hu B; Chai Y; Yoon C; Liu H; Liu Y; Shi J; Zhu T; Hu JC; Hu YF; Hou Y; Huang X; Yuen TT; Wang Y; Zhang J; Xia Y; Chen LL; Cai JP; Zhang AJ; Yuan S; Zhou J; Zhang BZ; Huang JD; Yuen KY; To KK; Chu H EBioMedicine; 2023 Sep; 95():104753. PubMed ID: 37579626 [TBL] [Abstract][Full Text] [Related]
23. Age-dependent acquisition of pathogenicity by SARS-CoV-2 Omicron BA.5. Imbiakha B; Ezzatpour S; Buchholz DW; Sahler J; Ye C; Olarte-Castillo XA; Zou A; Kwas C; O'Hare K; Choi A; Adeleke RA; Khomandiak S; Goodman L; Jager MC; Whittaker GR; Martinez-Sobrido L; August A; Aguilar HC Sci Adv; 2023 Sep; 9(38):eadj1736. PubMed ID: 37738347 [TBL] [Abstract][Full Text] [Related]
24. Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case. Tatham L; Kipar A; Sharp J; Kijak E; Herriott J; Neary M; Box H; Gallardo Toledo E; Valentijn A; Cox H; Pertinez H; Curley P; Arshad U; Rajoli RKR; Rannard S; Stewart JP; Owen A Microbiol Spectr; 2024 Aug; 12(8):e0391623. PubMed ID: 39012120 [TBL] [Abstract][Full Text] [Related]
25. Reduced Pathogenicity and Transmission Potential of Omicron BA.1 and BA.2 Sublineages Compared with the Early Severe Acute Respiratory Syndrome Coronavirus 2 D614G Variant in Syrian Hamsters. Su W; Choy KT; Gu H; Sia SF; Cheng KM; Nizami SIN; Krishnan P; Ng YM; Chang LDJ; Liu Y; Cheng SMS; Peiris M; Poon LLM; Nicholls JM; Yen HL J Infect Dis; 2023 May; 227(10):1143-1152. PubMed ID: 35776136 [TBL] [Abstract][Full Text] [Related]
26. The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus. Dong W; Mead H; Tian L; Park JG; Garcia JI; Jaramillo S; Barr T; Kollath DS; Coyne VK; Stone NE; Jones A; Zhang J; Li A; Wang LS; Milanes-Yearsley M; Torrelles JB; Martinez-Sobrido L; Keim PS; Barker BM; Caligiuri MA; Yu J J Virol; 2022 Jan; 96(1):e0096421. PubMed ID: 34668775 [TBL] [Abstract][Full Text] [Related]
27. Sex Differences in Lung Imaging and SARS-CoV-2 Antibody Responses in a COVID-19 Golden Syrian Hamster Model. Dhakal S; Ruiz-Bedoya CA; Zhou R; Creisher PS; Villano JS; Littlefield K; Ruelas Castillo J; Marinho P; Jedlicka AE; Ordonez AA; Bahr M; Majewska N; Betenbaugh MJ; Flavahan K; Mueller ARL; Looney MM; Quijada D; Mota F; Beck SE; Brockhurst J; Braxton AM; Castell N; Stover M; D'Alessio FR; Metcalf Pate KA; Karakousis PC; Mankowski JL; Pekosz A; Jain SK; Klein SL; mBio; 2021 Aug; 12(4):e0097421. PubMed ID: 34253053 [TBL] [Abstract][Full Text] [Related]
28. Infection, pathology and interferon treatment of the SARS-CoV-2 Omicron BA.1 variant in juvenile, adult and aged Syrian hamsters. Yuan L; Zhu H; Chen P; Zhou M; Ma J; Liu X; Wu K; Chen R; Liu Q; Yu H; Li L; Wang J; Zhang Y; Ge S; Yuan Q; Tang Q; Cheng T; Guan Y; Xia N Cell Mol Immunol; 2022 Dec; 19(12):1392-1399. PubMed ID: 36258005 [TBL] [Abstract][Full Text] [Related]
29. The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters. Abdelnabi R; Foo CS; Zhang X; Lemmens V; Maes P; Slechten B; Raymenants J; André E; Weynand B; Dallmeier K; Neyts J Antiviral Res; 2022 Feb; 198():105253. PubMed ID: 35066015 [TBL] [Abstract][Full Text] [Related]
30. Cellular tropism of SARS-CoV-2 in the respiratory tract of Syrian hamsters and B6.Cg-Tg(K18-ACE2)2Prlmn/J transgenic mice. Yen HL; Valkenburg S; Sia SF; Choy KT; Peiris JSM; Wong KHM; Crossland N; Douam F; Nicholls JM Vet Pathol; 2022 Jul; 59(4):639-647. PubMed ID: 34467820 [TBL] [Abstract][Full Text] [Related]
31. Antigenic cartography using variant-specific hamster sera reveals substantial antigenic variation among Omicron subvariants. Mühlemann B; Trimpert J; Walper F; Schmidt ML; Jansen J; Schroeder S; Jeworowski LM; Beheim-Schwarzbach J; Bleicker T; Niemeyer D; Richter A; Adler JM; Vidal RM; Langner C; Vladimirova D; Wilks SH; Smith DJ; Voß M; Paltzow L; Martínez Christophersen C; Rose R; Krumbholz A; Jones TC; Corman VM; Drosten C Proc Natl Acad Sci U S A; 2024 Aug; 121(32):e2310917121. PubMed ID: 39078681 [TBL] [Abstract][Full Text] [Related]
32. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Uraki R; Kiso M; Iida S; Imai M; Takashita E; Kuroda M; Halfmann PJ; Loeber S; Maemura T; Yamayoshi S; Fujisaki S; Wang Z; Ito M; Ujie M; Iwatsuki-Horimoto K; Furusawa Y; Wright R; Chong Z; Ozono S; Yasuhara A; Ueki H; Sakai-Tagawa Y; Li R; Liu Y; Larson D; Koga M; Tsutsumi T; Adachi E; Saito M; Yamamoto S; Hagihara M; Mitamura K; Sato T; Hojo M; Hattori SI; Maeda K; Valdez R; ; Okuda M; Murakami J; Duong C; Godbole S; Douek DC; Maeda K; Watanabe S; Gordon A; Ohmagari N; Yotsuyanagi H; Diamond MS; Hasegawa H; Mitsuya H; Suzuki T; Kawaoka Y Nature; 2022 Jul; 607(7917):119-127. PubMed ID: 35576972 [TBL] [Abstract][Full Text] [Related]
33. Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters. McMahan K; Giffin V; Tostanoski LH; Chung B; Siamatu M; Suthar MS; Halfmann P; Kawaoka Y; Piedra-Mora C; Jain N; Ducat S; Kar S; Andersen H; Lewis MG; Martinot AJ; Barouch DH Med; 2022 Apr; 3(4):262-268.e4. PubMed ID: 35313451 [TBL] [Abstract][Full Text] [Related]
35. Differential Outcomes of Infection by Wild-Type SARS-CoV-2 and the B.1.617.2 and B.1.1.529 Variants of Concern in K18-hACE2 Transgenic Mice. He Y; Henley J; Sell P; Comai L Viruses; 2023 Dec; 16(1):. PubMed ID: 38257760 [TBL] [Abstract][Full Text] [Related]
37. Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters. Rissmann M; Noack D; van Riel D; Schmitz KS; de Vries RD; van Run P; Lamers MM; Geurts van Kessel CH; Koopmans MPG; Fouchier RAM; Kuiken T; Haagmans BL; Rockx B Emerg Microbes Infect; 2022 Dec; 11(1):1778-1786. PubMed ID: 35787236 [TBL] [Abstract][Full Text] [Related]
38. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern. Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH Elife; 2022 Feb; 11():. PubMed ID: 35191378 [TBL] [Abstract][Full Text] [Related]
39. Comparison of the Pathogenicity of SARS-CoV-2 Delta and Omicron Variants by Analyzing the Expression Patterns of Immune Response Genes in K18-hACE2 Transgenic Mice. Kuruppuarachchi KAPP; Jang Y; Seo SH Front Biosci (Landmark Ed); 2022 Nov; 27(11):316. PubMed ID: 36472114 [TBL] [Abstract][Full Text] [Related]
40. Virological characteristics of SARS-CoV-2 Omicron BA.5.2.48. Wang W; Jin Q; Liu R; Zeng W; Zhu P; Li T; Wang T; Xiang H; Zhang H; Chen Q; Gao Y; Lai Y; Yan F; Xia X; Li J; Wang X; Gao Y Front Immunol; 2024; 15():1427284. PubMed ID: 39411709 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]